Hemab Therapeutics completed an upsized IPO in May 2026, raising $346.7 million to advance its rare bleeding disorder pipeline. The company reported Q1 2026 financial results showing a net loss and strong liquidity position.

• Hemab Therapeutics closed an upsized IPO raising $346.7 million to support advancement of its rare bleeding disorder pipeline [N1].
• As of March 31, 2026, the company held $49.86 million in cash and $113.67 million in short-term investments, with a current ratio of 12.85, indicating strong liquidity [S1].
• The company reported a net loss of $22.69 million for the three months ended March 31, 2026, reflecting ongoing investment in research and development [S1].

Hemab’s focused pipeline on rare bleeding disorders addresses significant unmet medical needs, with lead candidates in active clinical development stages. The successful completion of an upsized IPO provides substantial capital to support ongoing research and development activities. The company’s proprietary antibody technologies and strategic licensing agreements may enable it to develop differentiated therapies. If clinical trials progress successfully and regulatory approvals are obtained, Hemab could establish a strong position in the niche coagulation disorder market.

Hemab operates in a high-risk environment typical of clinical-stage biotech companies, with no approved products and ongoing net losses. Clinical development is costly and uncertain, with potential delays or failures in trials. The company depends on third parties for clinical trials and manufacturing, which may introduce execution risks. Competition from larger, established pharmaceutical companies is significant. The need for additional financing beyond current cash reserves poses a risk to sustained operations. Regulatory hurdles and intellectual property challenges could also adversely affect the company’s prospects.

Hemab Therapeutics’ moat is primarily based on its proprietary bispecific and monovalent antibody technologies targeting rare coagulation disorders, a niche with significant unmet medical needs. The company’s clinical-stage assets, sutacimig and HMB-002, represent innovative approaches in this specialized field. Intellectual property protection and licensing agreements with established biotech firms are critical to maintaining competitive advantage. However, the company faces substantial competition from other biotech and pharmaceutical companies developing coagulation therapies. The early clinical stage of its assets and reliance on third parties for development and manufacturing limit the current strength of its moat.

• Clinical Development Risk: The company’s product candidates are in early clinical stages, and there is uncertainty regarding successful completion of trials and regulatory approvals.
• Financial Risk: Hemab has incurred significant losses and depends on capital raises, including the recent IPO, to fund operations. Additional financing may be required.
• Execution Risk: Reliance on third parties for clinical trials and manufacturing may lead to delays or failures in development.
• Competitive Risk: The company faces substantial competition from other biotech and pharmaceutical firms developing coagulation disorder therapies.
• Regulatory and Intellectual Property Risk: Obtaining and maintaining regulatory approvals and intellectual property rights are critical and uncertain factors for the company’s success.

• Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders including Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease.
• The company’s lead product candidate is sutacimig (HMB-001), a bispecific antibody in Phase 1/2 clinical trials for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency.
• A second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for Von Willebrand Disease.
• The company also has multiple preclinical and discovery-stage assets under development.
• Hemab completed a corporate reorganization in March 2026, forming Hemab Therapeutics Holdings, Inc. as a Delaware holding company with Hemab ApS as a wholly owned subsidiary.
• The company completed an upsized IPO in May 2026, raising approximately $346.7 million to advance its rare bleeding disorder pipeline.
• As of March 31, 2026, Hemab had cash and cash equivalents of $49.86 million and short-term investments of $113.67 million, totaling approximately $163.5 million in liquid assets.
• The current ratio as of March 31, 2026, was 12.85, indicating strong short-term liquidity.
• The company reported a net loss of $22.69 million for the three months ended March 31, 2026, with basic and diluted EPS of -$23.98 per share.
• Operating expenses for Q1 2026 were $23.6 million, including $19.5 million in research and development and $4.15 million in general and administrative expenses.
• The company has incurred losses since inception and had an accumulated deficit of $204.5 million as of March 31, 2026.
• Hemab’s business model involves extensive preclinical and clinical development, regulatory approval processes, and eventual commercialization of novel therapies for rare bleeding disorders.
• The company relies on third parties for clinical trials and manufacturing, which introduces execution risks.
• Hemab faces competition from other pharmaceutical and biotechnology companies developing coagulation disorder therapies.
• The company’s ability to obtain and maintain intellectual property protection and comply with license agreements is critical to its business.
• The company’s IPO proceeds and existing cash are intended to fund operations and capital expenditures for at least one year from the date of the financial statements.
• The company is classified as a smaller reporting company and an emerging growth company, with all required SEC filings up to date as of May 2026.